Company research
IOVANCE BIOTHERAPEUTICS, INC.
CIK 1425205Updated Sep 27, 2026
SecurityIOVA · NASDAQ · equity
Name history
Lion Biotechnologies, Inc. · through Jun 5, 2017Genesis Biopharma, Inc · through Sep 23, 2013FREIGHT MANAGEMENT CORP · through Mar 8, 2010
IOVA price & chart
Loading TradingView…
NASDAQ:IOVA on TradingView ↗About the company
Biotherapeutics, Inc. Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at more than 95 authorized treatment centers. The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. For more information, please visit www.iovance.com.
In the news
Iovance Biotherapeutics to Present at Upcoming Conferences ↗
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment News provided by USA News Group Aug 14, 2025, 12:22 ET Share this article Share to X Share this article Share to X USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Aug. 14, 2025 /PRNew ↗
IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV News provided by DJS Law Group LLP Jul 14, 2025, 09:04 ET Share this article Share to X Share this article Share to X LOS ANGELES , July 14, 2025 /PR ↗
Recent filings
Other Events
Items 8.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Other Events
Items 8.01, 9.01
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 913,170,000Source | 910,426,000Source | 780,351,000Source | 663,982,000Source |
| Property, Plant and Equipment, NetUSD | 131,112,000Source | 109,081,000Source | 114,030,000Source | 105,232,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 163,078,000Source | 115,694,000Source | 114,888,000Source | 231,731,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 82,448,000Source | 69,340,000Source | 151,000Source | — |
| Inventory, NetUSD | 51,678,000Source | 51,520,000Source | 10,372,000Source | — |
| Assets, CurrentUSD | 442,689,000Source | 457,018,000Source | 307,848,000Source | 479,116,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 11,583,000Source | 12,377,000Source | 17,458,000Source | 7,271,000Source |
| Operating Lease, Right-of-Use AssetUSD | 45,899,000Source | 55,201,000Source | 62,515,000Source | 73,015,000Source |
| Other Assets, NoncurrentUSD | 8,166,000Source | 369,000Source | 270,000Source | 189,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 214,587,000Source | 200,021,000Source | 195,738,000Source | 164,344,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 17,000Source | 13,000Source | 11,000Source | 8,000Source |
| Additional Paid in CapitalUSD | 3,457,654,000Source | 3,095,987,000Source | 2,594,448,000Source | 2,068,867,000Source |
| Retained Earnings (Accumulated Deficit)USD | -2,775,530,000Source | -2,384,552,000Source | -2,012,375,000Source | -1,568,338,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 16,440,000Source | -1,046,000Source | 2,526,000Source | -902,000Source |
| Stockholders' Equity Attributable to ParentUSD | 698,583,000Source | 710,405,000Source | 584,613,000Source | 499,638,000Source |
| Liabilities and EquityUSD | 913,170,000Source | 910,426,000Source | 780,351,000Source | 663,982,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 138,358,000Source | 122,341,000Source | 110,306,000Source | 91,485,000Source |
| Operating Lease, Liability, CurrentUSD | 4,043,000Source | 12,896,000Source | 7,777,000Source | 12,587,000Source |
| Accounts Payable, CurrentUSD | 22,159,000Source | 27,509,000Source | 33,123,000Source | 26,603,000Source |
| Operating Lease, Liability, NoncurrentUSD | 44,401,000Source | 44,365,000Source | 67,085,000Source | 71,859,000Source |
| Deferred Income Tax Liabilities, NetUSD | 31,828,000Source | 32,315,000Source | 17,347,000Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 111,156,000Source | 81,936,000Source | 69,406,000Source | 52,295,000Source |
| Deferred Tax Liabilities, NetUSD | 31,828,000Source | 32,315,000Source | 17,347,000Source | — |
| Short-term InvestmentsUSD | 133,902,000Source | 208,087,000Source | 164,979,000Source | 240,114,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 12,862,000Source | 11,967,000Source | 11,568,000Source | 9,310,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 61,575,000Source | 109,627,000Source | 62,625,000Source | 84,022,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 13,108,000Source | 69,189,000Source | 149,000Source | — |
| Increase (Decrease) in InventoriesUSD | 14,211,000Source | 39,917,000Source | 10,118,000Source | — |
| Increase (Decrease) in Accounts PayableUSD | -6,661,000Source | -7,841,000Source | 4,828,000Source | 5,883,000Source |
| Deferred Income Tax Expense (Benefit)USD | -2,071,000Source | -2,828,000Source | -3,479,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -302,408,000Source | -352,977,000Source | -361,820,000Source | -292,757,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | 212,633,000Source | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 47,496,000Source | -96,411,000Source | -155,242,000Source | 256,455,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 33,836,000Source | 11,069,000Source | 22,290,000Source | 20,425,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 7,059,000Source | 12,858,000Source | 2,795,000Source | 2,649,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 300,773,000Source | 390,664,000Source | 462,959,000Source | 190,150,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 47,005,000Source | -59,265,000Source | -56,843,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 169,058,000Source | 122,053,000Source | 181,318,000Source | 238,161,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 0Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 1,144,000Source | -541,000Source | -2,740,000Source | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 23,077,000Source | 21,202,000Source | 9,849,000Source | — |
| DepreciationUSD | — | — | — | 9,300,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 238,000Source | 175,000Source | -70,000Source | — |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | -397,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -44,000Source | — | — | — |
| Gain (Loss) on Termination of LeaseUSD | — | 5,568,000Source | — | — |
| General and Administrative ExpenseUSD | 152,322,000Source | 153,017,000Source | 106,916,000Source | 104,097,000Source |
| Income Tax Expense (Benefit)USD | -2,071,000Source | -2,828,000Source | -3,479,000Source | — |
| Inventory Write-downUSD | 13,404,000Source | — | — | — |
| Investment Income, InterestUSD | 10,307,000Source | 20,273,000Source | 13,043,000Source | 2,985,000Source |
| Net Income (Loss) Attributable to ParentUSD | -390,978,000Source | -372,177,000Source | -444,037,000Source | -395,893,000Source |
| Operating ExpensesUSD | — | — | — | 398,878,000Source |
| Proceeds from Issuance of Common StockUSD | 306,307,000Source | 397,304,000Source | 463,281,000Source | 189,502,000Source |
| Proceeds from Stock Options ExercisedUSD | 15,000Source | 3,266,000Source | 63,000Source | 1,642,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | 61,575,000Source | 109,623,000Source | 62,625,000Source | 84,022,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | 54,000Source | 78,000Source | 940,000Source | -301,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 263,502,000Source | 164,070,000Source | 1,189,000Source | — |
| Cost of Goods and Services Sold | — | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Operating Income (Loss)USD | -403,356,000Source | -395,278,000Source | -460,559,000Source | -398,878,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -393,049,000Source | -375,005,000Source | -447,516,000Source | — |
| Income Tax Expense (Benefit)USD | -2,071,000Source | -2,828,000Source | -3,479,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -390,978,000Source | -372,177,000Source | -444,037,000Source | -395,893,000Source |
| Earnings Per Share, BasicUSD per share | -1.09Source | -1.28Source | -1.89Source | -2.49Source |
| Earnings Per Share, DilutedUSD per share | -1.09Source | -1.28Source | -1.89Source | -2.49Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 357,345Source | 289,877Source | 235,131Source | 159,259Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 357,345Source | 289,877Source | 235,131Source | 159,259Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 23,077,000Source | 21,202,000Source | 9,849,000Source | — |
| Costs and ExpensesUSD | 666,858,000Source | 559,348,000Source | 461,748,000Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 35,939,000Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 238,000Source | 175,000Source | -70,000Source | — |
| General and Administrative ExpenseUSD | 152,322,000Source | 153,017,000Source | 106,916,000Source | 104,097,000Source |
| Investment Income, InterestUSD | 10,307,000Source | 20,273,000Source | 13,043,000Source | 2,985,000Source |
| Operating ExpensesUSD | — | — | — | 398,878,000Source |
| Research and Development ExpenseUSD | 300,270,000Source | 282,336,000Source | 344,077,000Source | 294,781,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | 61,575,000Source | 109,623,000Source | 62,625,000Source | 84,022,000Source |
Filing attachments
tm2622463d1_ex99-1.htm · 8-K · 2026-08-06
EX-99.1 2 tm2622463d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 1 © 2026, Iovance Biotherapeutics, Inc. Corporate Overview August 2026 1 ───────────────────────────────────────── 2 © 2026, Iovance Biotherapeutics, Inc. Forward-Looking Statements Certain matters discussed in this presentation are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigatio…
Read attachment ↗tm2622322d1_ex99-1.htm · 8-K · 2026-08-06
EX-99.1 2 tm2622322d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates U.S. Amtagvi Revenue Reaches ~$91M and Total Revenue Increased 66% Year-over-Year Gross Margin Increased to 56% Fast Track Designation (FTD) Granted by the FDA for Lifileucel in Soft Tissue Sarcomas SAN CARLOS, Calif., August 6, 2026 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology…
Read attachment ↗tm2618989d1_ex99-1.htm · 8-K · 2026-07-02
EX-99.1 2 tm2618989d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 1 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Corporate Overview June 2026 1 2 © 2026, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this presentation are “forward - looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (t…
Read attachment ↗tm2613648d1_ex99-1.htm · 8-K · 2026-06-10
EX-99.1 2 tm2613648d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Iovance’s Amtagvi ® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., June 3, 2026 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel pol…
Read attachment ↗tm2613648d1_ex99-1.htm · 8-K · 2026-05-07
EX-99.1 2 tm2613648d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates 1Q26 Total Revenue of ~$71M Delivers ~45% Year-over-Year Growth 2Q26 Revenue Guidance of $86M to $88M and FY26 of $350M to $370M 40% Confirmed Objective Response Rate in Metastatic Serous Endometrial Cancer SAN CARLOS, Calif., May 7, 2026 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology …
Read attachment ↗tm266992d1_ex99-1.htm · 8-K · 2026-02-24
EX-99.1 2 tm266992d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates ~30% Quarterly Revenue Growth Driven by Amtagvi Demand Gross Margin Increased to 50% FY25 Revenue of $264M Achieved Annual Guidance U.S. FDA Fast Track Designation Granted for Lifileucel in Second-Line Advanced Non-Small Cell Lung Cancer SAN CARLOS, Calif., February 24, 2026 -- Iovance Biotherapeutic…
Read attachment ↗